This immunotoxin was achieved by conjugating/fusing the Anti-FCGR1A monoclonal antibody to ricin toxin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to acute myeloid leukemia (AML) cells. Then the ricin A chain is incorporated into the cell by receptor-mediated endocytosis, blocking ribosomal protein synthesis and ultimately leading to cell death. It was designed for treatment of acute myeloid leukemia.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.